Market capitalization | $1.12b |
Enterprise Value | $1.03b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 5.38 |
P/S ratio (TTM) P/S ratio | 5.83 |
P/B ratio (TTM) P/B ratio | 7.22 |
Revenue growth (TTM) Revenue growth | 17.53% |
Revenue (TTM) Revenue | $191.43m |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
2 Analysts have issued a Silk Road Medical, Inc. forecast:
2 Analysts have issued a Silk Road Medical, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 191 191 |
18%
18%
|
|
Gross Profit | 142 142 |
21%
21%
|
|
EBITDA | -56 -56 |
14%
14%
|
EBIT (Operating Income) EBIT | -60 -60 |
13%
13%
|
Net Profit | -57 -57 |
7%
7%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Silk Road Medical, Inc. develops and manufactures medical devices to treat neurovascular diseases. The firm's devices enable vascular access via a puncture adjacent to the collarbone instead of the traditional approach of accessing the vascular system through the groin. Its products include ENROUTE Transcarotid Neuroprotection & Stent System. The company was founded by Tony M. Chou and Michi Garrison on March 21, 2007 and is headquartered in Sunnyvale, CA.
Head office | United States |
CEO | Charles McKhann |
Employees | 474 |
Founded | 2007 |
Website | www.silkroadmed.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.